PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas - Implications for Akt activation

Oncology Reports

Volumn 19, Issue 5, 2008, Pages 1141-1147

  Hennenlotter, Joerg ^a   Ohneseit, Petra A ^a   Simon, Perikles ^a   Merseburger, Axel S ^a   Serth, Juergen ^b   Kuehs, Ursula ^a   Kramer, Mario ^a   Hartmann, Joerg T ^a   Stenzl, Arnulf ^a   Kuczyk, Markus A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Akt; p27Kipl; PTEN; Renal cell cancer; RT PCR

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P27; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FEMALE; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; TUMOR GROWTH; WESTERN BLOTTING; BIOSYNTHESIS; DNA MICROARRAY; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; KIDNEY; KIDNEY TUMOR; METABOLISM; METASTASIS; METHODOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 47549105551     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.5.1141     Document Type: Article

References (38)

1. Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumours. J Pathol 183: 131-133, 1997.
2. Novick: Renal Tumours. In: Campbell's Urology. Walsh (ed.) WB Saunders, Philadelphia, pp2672-2731, 2002.
3. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R and Brooks JD: Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med 3: e13, 2006.
4. Patard JJ, Rioux-Leclercq N and Fergelot P: Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49: 633-643, 2006.
5. Patel PH, Chaganti RS and Motzer RJ: Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94: 614-619, 2006.
6. Song G, Ouyang G and Bao S: The activation of Akt/PKB signalling pathway and cell survival. J Cell Mol Med 9: 59-71, 2005.
7. Samuels Y and Ericson K: Oncogenic PI3K and its role in cancer. Curr Opin Oncol 18: 77-82, 2006.
8. Altomare DA and Testa JR: Perturbations of the AKT signalling pathway in human cancer. Oncogene 24: 7455-7464, 2005.
9. Khaleghpour K, Li Y, Banville D, Yu Z and Shen SH: Involvement of the PI 3-kinase signaling pathway in the progression of colon adenocarcinoma. Carcinogenesis 25: 241-248, 2004.
10. Kondo K, Yao M, Kobayashi K, et al: PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 91: 219-224, 2001.
11. Alimov A, Li C, Gizatullin R, et al: Somatic mutation and homozygous deletion of PTEN/MMAC1 gene of 10q23 in renal cell carcinoma. Anticancer Res 19: 3841-3846, 1999.
12. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG and Thuroff JW: Loss of tumour-suppressor protein PTEN during renal carcinogenesis. Int J Cancer 99: 53-57, 2002.
13. Hara S, Oya M, Mizuno R, Horiguchi A, Marumo K and Murai M: Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor. Ann Oncol 16: 928-933, 2005.
14. Horiguchi A, Oya M, Uchida A, Marumo K and Murai M: Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. J Urol 169: 710-713, 2003.
15. Osipov V, Keating JT, Faul PN, Loda M and Datta MW: Expression of p27 and VHL in renal tumours. Appl Immunohistochem Mol Morphol 10: 344-350, 2002.
16. Vazquez F and Sellers WR: The PTEN tumour- suppressor protein: an antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta 1470: M21 -M35, 2000.
17. Slingerland J and Pagano M: Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 183: 10-17, 2000.
18. Migita T, Oda Y, Naito S and Tsuneyoshi M: Low expression of p27 (Kip1) is associated with tumour size and poor prognosis in patients with renal cell carcinoma. Cancer 94: 973-979, 2002.
19. Hedberg Y, Davoodi E, Ljungberg B, Roos G and Landberg G: Cyclin E and p27 protein content in human renal cell carcinoma: clinical outcome and associations with cyclin D. Int J Cancer 102: 601-607, 2002.
20. van Spronsen DJ, de Weijer KJ, M ulders PF and De Mulder PH: Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs 16: 709-717, 2005.
21. Sobin LH: TNM Classification of Malignant Tumours. International Union Against Cancer (UICC) 6th edition Sobin LH (ed.), New York, pp193-195, 2002.
22. Fuhrman SA, Lasky LC and Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6: 655-663, 1982.
23. Eble JN: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organisation Classification of Tumours. Eble JN, Sauter G and Epstein JI (ed.) IARC Press, Lyons, p7, 2004.
24. Merseburger AS, Anastasiadis AG, Hennenlotter J, et al: Tissue microarrays: applications in urological cancer research. World J Urol (In press).
25. Theodorescu D, Broder SR, Boyd JC, Mills SE and Frierson UF Jr: Cathepsin D and chromogranin A as predictors of long-term disease-specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80: 2109-2119, 1997.
26. Simon P, Schott K, Williams RW and Schaeffel F: Post-transcriptional regulation of the immediate-early gene EGR1 by light in the mouse retina. Eur J Neurosci 20: 3371-3377, 2004.
27. Simon P: Q-Gene: processing quantitative real-time RT-PCR data. Bioinformatics 19: 1439-1440, 2003.
28. Ma DZ, Xu Z, Liang YL, et al: Down-regulation of PTEN expression due to a loss of promoter activity in human hepatocellular carcinoma cell lines. World J Gastroenterol 11: 4472-4477, 2005.
29. Shin Lee J, Seok Kim H, Bok Kim Y, Cheol Lee M and Soo Park C: Expression of PTEN in renal cell carcinoma and its relation to tumour behavior and growth. J Surg Oncol 84: 166-172, 2003.
30. Kim HL, Seligson D, Liu X, Janzen N, Bui MHT, Yu H, Shi T, Belldegrun AS, Horvath S, Figlin RA: Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 173: 1496-1501, 2005.
31. KIP1 in multistage colorectal carcinogenesis. Cancer Res 58: 114-122, 1998.
32. Chiarle R, Pagano M and Inghirami G: The cyclin-dependent kinase inhibitor p27 and its prognostic role in breast cancer. Breast Cancer Res 3: 91-94, 2001.
33. Kip1 at Thr- 157 interferes with its association with importin a during G1 and prevents nuclear re-entry. J Biol Chem 280: 6055-6063, 2005.
34. Viglietto G, Motti ML, Bruni P, et al: Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27 (Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136-1144, 2002.
35. Kip1 expression. Oncol Rep 10: 1717-1722, 2003.
36. Packer L, Pavey S, Parker A, et al: Osteopontin is a downstream effector of the P13-kinase pathway in melanomas that is inversely correlated with functional PTEN. Carcinogenesis 27: 1778-1786, 2006.
37. Adams EJ, Green JA, Clark AH and Youngson JH: Comparison of different scoring systems for immunohistochemical staining. J Clin Pathol 52: 75-77, 1999.
38. Horstmann M, Merseburger AS, von der Heyde E, et al: Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol 131: 715-722, 2005.